Boehringer touts Pradaxa antidote data as FDA decision nears

LONDON--Boehringer Ingelheim's Pradaxa currently trails Johnson & Johnson ($JNJ) and Bayer med Xarelto in the market for new-age anticoagulants, but the German drugmaker is hoping a nod for its antidote candidate will help turn the tide in its favor. On Tuesday, the company touted positive data in support of that candidate: In 39 patients who required emergency surgery, the experimental antidote, idarucizumab, reversed the effects of Pradaxa with a median 1.7 hours between administering the drug and starting a procedure, a late-stage trial analysis showed. More from FiercePharmaMarketing

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.